Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
86.49
+1.23 (1.44%)
At close: Jul 2, 2026, 4:00 PM EDT
85.00
-1.49 (-1.72%)
After-hours: Jul 2, 2026, 6:46 PM EDT
Cytokinetics Employees
Cytokinetics had 673 employees as of December 31, 2025. The number of employees increased by 175 or 35.14% compared to the previous year.
Employees
673
Change (1Y)
175
Growth (1Y)
35.14%
Revenue / Employee
$157,229
Profits / Employee
-$1,232,704
Market Cap
11.74B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 673 | 175 | 35.14% |
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| Krystal Biotech | 295 |
CYTK News
- 3 days ago - Cytokinetics upgraded to Buy from Neutral at UBS - TheFly
- 8 days ago - Cytokinetics price target raised to $118 from $100 at Mizuho - TheFly
- 15 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Cytokinetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program - GlobeNewsWire
- 4 weeks ago - Cytokinetics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Cytokinetics launches Myqorzo in Germany - TheFly
- 4 weeks ago - Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - GlobeNewsWire